FAE: Revenue up 12.3% to €307.4M, with strong pharma and animal health growth; outlook remains positive
· Issued by Faes Farma, S.A.
Revenue grew 12.3% to €307.4M, led by pharma and animal health divisions, with strategic molecules up 16%. Adjusted EBITDA rose 2.5%, while net profit fell 10.5% due to one-off costs. Outlook remains strong with continued organic and M&A-driven growth.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
